BOULDER, Colo., June 17, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated ...
Brickell filed a motion to dismiss the complaint filed by Bodor Labs and Nicholas S. Bodor in federal court Brickell initiated arbitration proceedings against Bodor Labs and Nicholas S. Bodor ...
Expect to initiate Phase 1 clinical study of lead DYRK1A inhibitor program, BBI-02, a potential first-in-class oral treatment for autoimmune and inflammatory diseases, in 2022 Acquisition includes ...
BOULDER, Colo., July 01, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by ...
MIAMI--(BUSINESS WIRE)--Brickell Biotech, Inc. (“Brickell”), a clinical-stage pharmaceutical company focused on the development of differentiated, innovative therapeutics to satisfy current unmet ...
Brickell Biotech Inc (NASDAQ: BBI) has entered into an exclusive agreement with Carna Biosciences Inc to develop and commercialize Carna's portfolio of oral Stimulator Interferon Genes (STING) ...
BOULDER, Colo. -- Brickell Biotech, Inc. (BBI) on Wednesday reported a loss of $5.1 million in its second quarter. The Boulder, Colorado-based company said it had a loss of 43 cents per share.
Anglo-Australian miner Rio Tinto , said on Wednesday that it will streamline operations into three business units, Iron Ore, Aluminium & Lithium, and Copper, with Matthew Holcz appointed to lead the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback